The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
本发明提供了用于治疗或改善精神障碍的
大麻素 2 型(CB2)受体反向激动剂。本发明进一步提供了包含 4′-O-methylhonokiol 的药物组合物,用于治疗注意缺陷多动障碍(ADHD)和抽动秽语综合征。